EA201792509A1 - Лечение рака - Google Patents

Лечение рака

Info

Publication number
EA201792509A1
EA201792509A1 EA201792509A EA201792509A EA201792509A1 EA 201792509 A1 EA201792509 A1 EA 201792509A1 EA 201792509 A EA201792509 A EA 201792509A EA 201792509 A EA201792509 A EA 201792509A EA 201792509 A1 EA201792509 A1 EA 201792509A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
nuc
stem cells
cancer stem
targeting
Prior art date
Application number
EA201792509A
Other languages
English (en)
Russian (ru)
Inventor
Хью Гриффит
Крис Макгиган
Крис Пеппер
Original Assignee
НУКАНА ПиЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53276184&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201792509(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by НУКАНА ПиЭлСи filed Critical НУКАНА ПиЭлСи
Publication of EA201792509A1 publication Critical patent/EA201792509A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EA201792509A 2015-05-14 2015-05-14 Лечение рака EA201792509A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2015/051438 WO2016181093A1 (en) 2015-05-14 2015-05-14 Cancer treatments

Publications (1)

Publication Number Publication Date
EA201792509A1 true EA201792509A1 (ru) 2018-05-31

Family

ID=53276184

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792509A EA201792509A1 (ru) 2015-05-14 2015-05-14 Лечение рака

Country Status (26)

Country Link
US (3) US20180289733A1 (cg-RX-API-DMAC7.html)
EP (2) EP3197456B2 (cg-RX-API-DMAC7.html)
JP (1) JP6761852B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180021697A (cg-RX-API-DMAC7.html)
CN (2) CN115837028A (cg-RX-API-DMAC7.html)
AU (2) AU2015394135B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017024461B1 (cg-RX-API-DMAC7.html)
CA (1) CA2985540C (cg-RX-API-DMAC7.html)
CY (1) CY1120516T1 (cg-RX-API-DMAC7.html)
DK (1) DK3197456T3 (cg-RX-API-DMAC7.html)
EA (1) EA201792509A1 (cg-RX-API-DMAC7.html)
ES (1) ES2668377T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180762T1 (cg-RX-API-DMAC7.html)
HU (1) HUE038541T2 (cg-RX-API-DMAC7.html)
IL (1) IL255591B (cg-RX-API-DMAC7.html)
LT (1) LT3197456T (cg-RX-API-DMAC7.html)
MX (2) MX390506B (cg-RX-API-DMAC7.html)
MY (1) MY192081A (cg-RX-API-DMAC7.html)
PH (1) PH12017502086B1 (cg-RX-API-DMAC7.html)
PL (1) PL3197456T3 (cg-RX-API-DMAC7.html)
PT (1) PT3197456T (cg-RX-API-DMAC7.html)
RS (1) RS57371B1 (cg-RX-API-DMAC7.html)
SI (1) SI3197456T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800303T1 (cg-RX-API-DMAC7.html)
TR (1) TR201806642T4 (cg-RX-API-DMAC7.html)
WO (1) WO2016181093A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
DK3031812T3 (en) 2011-03-01 2018-09-17 NuCana plc CHEMICAL COMPOUNDS
SI3150616T1 (sl) 2012-11-16 2017-08-31 University College Cardiff Consultants Limited Mešanica rp/sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
WO2015198059A1 (en) 2014-06-25 2015-12-30 Nucana Biomed Limited Formulation comprising a gemcitabine-prodrug
EP3160978B1 (en) 2014-06-25 2020-07-29 NuCana plc Gemcitabine prodrugs
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
LT3224268T (lt) 2014-11-28 2019-09-25 NuCana plc Naujieji 2` ir (arba) 5` aminorūgšties esterio fosforamidato 3`-deoksi adenozino dariniai, kaip priešvėžiniai junginiai
BR112018003594A2 (pt) 2015-09-25 2018-09-25 Hoffmann La Roche cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados
PH12018500691B1 (en) 2015-10-05 2022-08-10 NuCana plc Combination therapy
RS62593B1 (sr) 2015-12-11 2021-12-31 NuCana plc Dijastereoselektivna sinteza derivata fosfata i proleka gemcitabina nuc-1031
HUE050290T2 (hu) * 2015-12-23 2020-11-30 NuCana plc Kombinált terápia
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
CA3008769A1 (en) * 2015-12-23 2017-06-29 NuCana plc Combination therapy comprising nuc-1031 and cisplatin
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) * 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
EP3863674A2 (en) 2018-10-12 2021-08-18 The Regents of the University of Colorado, a body corporate Compositions and methods for reducing cancer stem cells
CN117462555B (zh) * 2021-01-31 2025-12-30 兰州大学 6-巯基鸟嘌呤在制备预防和/或治疗酒精性胃溃疡药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
HRP20160625T1 (hr) * 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
EP2274617A4 (en) * 2008-04-10 2011-11-09 Massachusetts Inst Technology METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS

Also Published As

Publication number Publication date
WO2016181093A1 (en) 2016-11-17
JP2018515618A (ja) 2018-06-14
AU2015394135B2 (en) 2021-09-16
EP3197456B1 (en) 2018-04-04
HUE038541T2 (hu) 2018-10-29
EP3415149A1 (en) 2018-12-19
BR112017024461B1 (pt) 2023-04-04
AU2015394135A1 (en) 2017-12-14
BR112017024461A2 (pt) 2018-07-24
DK3197456T3 (en) 2018-06-06
MY192081A (en) 2022-07-26
US20230226092A1 (en) 2023-07-20
PL3197456T3 (pl) 2018-09-28
US20210100825A1 (en) 2021-04-08
IL255591A (en) 2018-01-31
JP6761852B2 (ja) 2020-09-30
KR20180021697A (ko) 2018-03-05
EP3197456B2 (en) 2023-10-11
SMT201800303T1 (it) 2018-07-17
CA2985540A1 (en) 2016-11-17
CY1120516T1 (el) 2019-07-10
US20180289733A1 (en) 2018-10-11
MX390506B (es) 2025-03-20
RS57371B1 (sr) 2018-08-31
CN115837028A (zh) 2023-03-24
PH12017502086B1 (en) 2022-12-09
TR201806642T4 (tr) 2018-06-21
MX2017014544A (es) 2018-09-26
PH12017502086A1 (en) 2018-04-30
SI3197456T1 (en) 2018-08-31
MX374946B (es) 2025-03-06
LT3197456T (lt) 2018-07-10
IL255591B (en) 2021-10-31
CA2985540C (en) 2021-08-24
CN107835687A (zh) 2018-03-23
EP3197456A1 (en) 2017-08-02
ES2668377T3 (es) 2018-05-17
MX2020009154A (es) 2022-03-08
HRP20180762T1 (hr) 2018-08-24
AU2021277614A1 (en) 2021-12-23
PT3197456T (pt) 2018-05-22

Similar Documents

Publication Publication Date Title
EA201792509A1 (ru) Лечение рака
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
BR112017020895A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
MX391981B (es) Derivados de benzooxazol como inmunomoduladores.
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
EA201692511A1 (ru) Комбинированное лечение ингибиторами глутаминазы
MX391720B (es) Terapia combinada para tratar cáncer.
BR112015026307A2 (pt) heterociclo bicíclicos como inibidores de fgfr
BR112017017727A2 (pt) heterociclos bicíclicos como inibidores de fgfr4
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
MX383484B (es) Método para tratar el cáncer.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
BR112015032595A2 (pt) inibidores de ido
MX2018002344A (es) Metodo para tratar el cancer.
MX376201B (es) Compuestos inhibidores de metaloenzima.
MX375716B (es) Método para tratar adenocarcinoma de pulmón.
MX2021015826A (es) Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112017021312A2 (pt) tratamento de câncer de pulmão com inibidores de glutaminase
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
MX382996B (es) Inhibidores de pcna
MX394452B (es) Inhibicion de la actividad de olig2.
MX390320B (es) Farmaco de combinacion.
MX394015B (es) Inhibición de la actividad de la olig2.